Previous Article | Next Article 
Journal of Virology, May 1999, p. 3702-3708, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Prevalent Class I-Restricted T-Cell Response to the Theiler's
Virus Epitope Db:VP2121-130 in the Absence of
Endogenous CD4 Help, Tumor Necrosis Factor Alpha, Gamma Interferon,
Perforin, or Costimulation through CD28
Aaron J.
Johnson,1
M. Kariuki
Njenga,2
Michael J.
Hansen,1
Scott T.
Kuhns,1
Lieping
Chen,1
Moses
Rodriguez,2 and
Larry
R.
Pease1,*
Departments of
Immunology1 and
Neurology,2 Mayo Clinic and
Foundation, Rochester, Minnesota 55905
Received 6 November 1998/Accepted 21 January 1999
 |
ABSTRACT |
C57BL/6 mice mount a cytotoxic T-lymphocyte (CTL) response against
the Daniel's strain of Theiler's murine encephalomyelitis virus
(TMEV) 7 days after infection and do not develop persistent infection
or the demyelinating syndrome similar to multiple sclerosis seen in
susceptible mice. The TMEV capsid peptide VP2121-130 sensitizes H-2Db+ target cells for killing by
central-nervous-system-infiltrating lymphocytes (CNS-ILs) isolated from
C57BL/6 mice infected intracranially. Db:VP2121-130 peptide tetramers were used
to stain CD8+ CNS-ILs, revealing that 50 to 63% of these
cells bear receptors specific for VP2121-130 presented
in the context of Db. No T cells bearing this specificity
were found in the cervical lymph nodes or spleens of TMEV-infected
mice. H-2b mice lacking CD4, class II, gamma
interferon, or CD28 expression are susceptible to persistent virus
infection but surprisingly still generate high frequencies of
CD8+, Db:VP2121-130-specific T
cells. However, CD4-negative mice generate a lower frequency of
Db:VP2121-130-specific T cells than do
class II negative or normal H-2b animals.
Resistant tumor necrosis factor alpha receptor I knockout mice also
generate a high frequency of CD8+ CNS-ILs specific for
Db:VP2121-130. Furthermore, normally
susceptible FVB mice that express a Db transgene generate
Db:VP2121-130-specific CD8+
CNS-ILs at a frequency similar to that of C57BL/6 mice. These results demonstrate that VP2121-130 presented in the
context of Db is an immunodominant epitope in TMEV
infection and that the frequency of the
VP2121-130-specific CTLs appears to be
independent of several key inflammatory mediators and genetic
background but is regulated in part by the expression of CD4.
 |
INTRODUCTION |
The Daniel's strain of Theiler's
murine encephalomyelitis virus (TMEV) is a picornavirus which upon
intracerebral injection causes a persistent infection of the white
matter and demyelination in susceptible mouse strains (haplotypes
H-2s,
H-2r,
H-2v,
H-2f,
H-2p, or
H-2q) but not in resistant strains
(haplotypes H-2b,
H-2d, or
H-2k) of the C57BL lineage (35, 41,
44). The demyelinating disease observed in susceptible strains of
mice is an excellent model of human multiple sclerosis (6, 12,
27). While the cause of pathology in susceptible strains remains
unknown, the Th1 CD4+ compartment has been demonstrated to
mediate a delayed-type hypersensitivity inflammatory reaction with
macrophages and cytokines leading to destruction of self tissue
(26). However, depletion of the CD8+ T-cell
compartments has been shown to suppress demyelination, whereas
depletion of CD4+ T cells promotes demyelination
(39). In addition, efforts to inhibit the effects of CD4 or
CD8 T-cell involvement by disrupting major histocompatibility complex
(MHC) class I and II expression or by knocking out CD4 and CD8 still
results in demyelination and high virus titers (13, 14, 34, 37,
40). Therefore, the contribution of CD4 and CD8 T-cell subsets to
demyelination in susceptible strains remains obscure.
In contrast to susceptible strains of mice, resistant mice clear TMEV
from the central nervous system (CNS), and this clearance is associated
with a virus-specific cytotoxic T-lymphocyte (CTL) response
(43). Evidence supporting the importance of the CTL response
in TMEV is indirect, but an essential role for a class I restricted
response in viral clearance is demonstrated by several observations.
First, the susceptible DBA/2 mice upon in vivo administration of
interleukin-2 (IL-2)-secreting tumor readily clear TMEV.
The viral clearance correlated with a three- to fourfold increase in
virus-specific CTL activity (18). Second,
perforin-deficient mice develop persistent TMEV infection
(45). Perforin is an important effector molecule for both
CTL and natural killer (NK) cells. Immunodepletion of NK cells in
genetically resistant mice with anti-NK 1.1 antibody does not allow
TMEV virus persistence, whereas a more pervasive depletion with
anti-asialo GM1, which also targets some activated T cells, does
(36). Third, the
2 microglobulin
(
2m) knockout mice crossed onto the resistant
C57BL/6 genetic background are no longer able to clear the virus
(13, 37, 40). Finally, resistance has been genetically
mapped to the H-2D class I alleles, since introduction
of H-2Db and H-2Dd
transgenes into susceptible strains of mice allows TMEV clearance (2, 21, 38, 41, 42). The use of MHC recombinant mice suggests that H-2D class I alleles, more effectively than
H-2K class I alleles, present viral peptides to CTLs which
leads to TMEV clearance, either by direct killing of infected cells or by cytokine release (21, 42).
Support for the hypothesis that the H-2D class I molecules
effectively present viral peptides to CTLs during viral clearance was
demonstrated by two groups simultaneously. Borson et al. (5) subjected a VP2 viral capsid fusion protein to alkali hydrolysis and
used the resulting peptides to sensitize RMA-S target cells for
killing by C57BL/6 CNS infiltrating lymphocytes (CNS-ILs). Viral protein 2 (VP2) amino acids 112 to 140 were identified as containing the relevant epitope. Upon synthesizing overlapping peptides from this region, VP2121-130
(FHAGSLLVFM) was identified as the peptide that
could sensitize target cells for CNS-IL killing. Independently,
Dethlefs et al. (11) identified a 9-amino-acid peptide
from VP2, amino acids 122 to 130, which is found in the VP2 capsid
protein of both Mengo virus and TMEV. This peptide sensitized target
cells for CTLs isolated from both Mengo virus- and TMEV-infected
mice. While both of these studies found a relevant epitope for
TMEV-specific CTL killing, the relative importance of
VP2121-130 for CTL mediated clearance of TMEV from the CNS in resistant C57BL/6 mice was not determined.
To better understand the class I-mediated T-cell response and the
importance of VP2121-130 presented in the context of
Db in a TMEV clearing inflammatory reaction, we constructed
peptide-MHC tetramers. Altman et al. have described a method by
which four class I heterodimers bound with a specific peptide can be
assembled with fluorescent, conjugated streptavidin and used to
stain T cells with T-cell receptors (TCRs) that have affinity for
the peptide presented in the context of the class I molecule
(1). Using this method, we assembled tetramers of
Db, VP2121-130, and human
2m to stain CD8+ T cells with TCRs specific
for this epitope and then assessed their frequency in the bulk
population of brain-infiltrating CD8+ lymphocytes. In
addition, we addressed the importance of the CD4 and CD8 T-cell
compartments, the H-2Db allele, gamma
interferon (IFN-
), tumor necrosis factor alpha receptor I
(TNF-
RI), perforin, MHC class II, and CD28 in
VP2121-130-specific T-cell infiltration by using
knockout mice as hosts for intracerebral viral infection.
 |
MATERIALS AND METHODS |
Virus infection and mice.
Male and female C57BL/6,
C57BL/6-Pfptm1sdz, and IFN-
/
mice were
obtained from Jackson Laboratory (Bar Harbor, Maine), and the
Abo (class II
/
) mice were a gift from Chris
Benoist (Strasbourg, France). All other knockout mice
(CD4
/
, CD8
/
,
TNF-
RI
/
, and CD28
/
) were gifts from
Tak Mak at Amgen (Thousand Oaks, Calif.). The FVB/Db mice
were generated with a Db genomic transgene in Chella
David's gene transfer lab at the Mayo Foundation (Rochester, Minn.).
Mice ranged in age from 4 to 16 weeks. Mouse spleens, lymph nodes, and
brains were harvested 7 days post-intracerebral injection with 2 × 106 PFU of Daniel's strain of TMEV. Lymphocytes were
then extracted from the brain through homogenization and a homogeneous
Percol gradient (24). An improved step gradient containing
35% Percol layered over 70% Percol was used to isolate cleaner
preparations of lymphocytes from brains (see Fig. 4). The change in
isolation procedures did not alter the ratio of tetramer. Stained
CD8+ T cells observed in C57BL/6 mice were infected with
TMEV (data not shown). Erythrocytes were then removed from brain,
spleen, and lymph node cell preparations through lysis with ammonium
chloride, potassium carbonate, and EDTA (ACK). Handling of all
animals conformed to the National Institutes of Health and Mayo Clinic
institutional guidelines.
Preparation of H-2Db tetramers.
The
expression vectors for H-2Db and human
2m were generous gifts from John Altman and Mark Davis,
respectively. Proteins expressed from these reagents in bacteria were
isolated and folded in gross excess of E7 or
VP2121-130 peptide as previously described (15,
25, 38). The folded monomer complexes were desalted with a PD-10
desalting column (Pharmacia, Upsala, Sweden), biotinylated with a BirA
biotinylation kit (Avidity, Denver, Colo.), purified with a Mono Q
cation-exchange column (Bio-Rad, Hercules, Calif.), and complexed with
R-phycoerythrin-streptavidin (Molecular Probes, Eugene,
Oreg.) at a 4.1:1 molar ratio. This tetramer complex was then purified
by S-200 size exclusion gel filtration (Bio-Rad).
Flow cytometric analysis.
Then, 106 cells
isolated from brain, lymph nodes, and spleen were stained with
R-phycoerythrin Db:VP2121-130 tetramer for
1 h, adding anti-CD8 fluorescein isothiocyanate during the final
20 minutes. Samples were then washed twice with fluorescence-activated
cell sorter (FACS) buffer (1% bovine serum albumin and 2% sodium
azide), resuspended in cold phosphate-buffered saline and fixed in 1%
paraformaldehyde. Samples were run on a Becton Dickinson FACScan
instrument (Mountain View, Calif.) and are reported on a logarithmic
scale (250 channels/log intensity). Gates were drawn to include
CD8+ cells while excluding nonspecific binding of tetramer
and/or anti-CD8. The data were analyzed in two ways. First, the
quadrants were positioned to exclude the lymphocyte-negative signals
present in normal, uninfected brain cell preparations (Fig.
1A) so that only CD8+ cells
would be scored. This procedure counts only cells expressing higher
levels of CD8 and misses some positive cells that coincide in
fluorescent intensity with the negative background. Although this
approach has the disadvantage of not analyzing all the cells, it has
the advantage of being objectively applied to all of the samples
analyzed in a given experiment. In a second approach, we drew gates
around populations of fluorescent cells not present in the normal brain
preparation (Fig. 1A). We defined two CD8+ populations in
Fig. 1B: cells staining with the tetramer and cells not staining with
the tetramer. The estimated ratios of tetramer-stained to nonstained
cells by using either method was the same. These two strategies were
applied to all the FACS data presented; both yielded comparable
results.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 1.
Staining of inflammatory mononuclear cells isolated from
the brains of noninfected C57BL/6 mice (A), TMEV-infected C57BL/6 mice
(B), and TMEV-infected BALB/c mice (C). The circles population
represents those lymphocytes that stain with both anti-CD8 and
Db:VP2121-130 tetramer. The percentage
given is the percentage of CD8+ lymphocytes that stain with
Db:VP2121-130 tetramer. This value is
corrected by subtracting the nonspecific binding of irrelevant
Db:E7 tetramer. See Materials and Methods for details of
the analysis.
|
|
In vitro CTL assay.
A standard 4-h 51Cr release
assay was done to determine CTL activity in splenocyte and CNS-IL
preparations, and 103 RMA-S target cells/well were used.
RMA-S cells were labeled with 51Cr for 2 h in the
presence of VP2121-130 peptide or irrelevant Kb-restricted dEV8 peptide (49). Both peptides
were synthesized in the Mayo protein core facility. Freshly isolated
effector cells were incubated with labeled target cells for 4 h.
The percent specific lysis of target cells was calculated from released
51Cr as follows: 100 × (experimental release
spontaneous release)/(total release in detergent
spontaneous
release). The number of effector T cells added was estimated by
counting the cells with lymphocyte morphology by microscopic
inspection. Samples from the cell preparations were analyzed by FACS
and found to contain fewer T cells than was estimated by microscopy.
These effector/target ratios of brain cell preparations represent
overestimates of the T cells added. This fact does not influence our
conclusions, since populations containing fewer T cells exhibited
cytolytic activity, while populations containing more T cells did not.
 |
RESULTS AND DISCUSSION |
Inflammatory mononuclear cells were isolated from the whole
brains of noninfected and 7-day-post-TMEV-infected C57BL/6 mice. These CNS-ILs were stained with anti-CD8 antibody and
Db:VP2121-130 tetramer or control tetramer
specific for an irrelevant papillomavirus epitope as outlined in
Materials and Methods. As expected, no CNS-ILs were detected in the
brains from noninfected mice and no cells had demonstrable staining
with anti-CD8 antibodies or
Db:VP2121-130 tetramer (Fig. 1A). In
contrast, as determined by four separate experiments, approximately 50 to 63% of CNS-ILs from TMEV-infected mice stained double positive for
both of these reagents (Fig. 1B). BALB/c
(H-2d) mice infected with TMEV did not
stain with the Db:VP2121-130 tetramer
(Fig. 1C). These observations document the specificity of the tetramer
staining and demonstrate that a majority of CD8+ T cells in
C57BL/6 mice harvested from the site of viral infection express TCR
specific for the VP2121-130 peptide presented in the
context of Db. Three-color staining revealed that the
analyzed T-cell populations included approximately 30%
CD4+/CD8
cells that are presumably T helper
cells (data not shown). None of these cells bear receptors stained by
the tetramer probes.
To address whether there was a systemic clonal expansion of
CD8+ T cells specific for the
Db:VP2121-130 epitope, lymphocytes were
isolated from the brain, spleen, and cervical lymph nodes of infected
C57BL/6 mice. No VP2121-130-specific T cells were
identified in the spleen or cervical lymph nodes, whereas 55%
of the CD8+ cells in the brain stained with the
Db:VP2121-130 tetramer (Fig.
2A to C). A control tetramer, consisting
of Db loaded with a Db binding peptide from the
human papillomavirus E7 protein (25), did not stain this
population (Fig. 2F). This control tetramer, however, stains greater
than 99% of Db:E7 epitope-specific CD8+ T
cells (data not shown). The observation that 55% of the CTLs are
specific for one peptide is similar to frequencies previously reported in infections with lymphocytic choriomeningitis virus (LCMV).
For example, Murali-Krishna et al., by using tetramers constructed with
an immunodominant LCMV peptide presented in the context of
Ld, stained up to 56% of splenic CD8+ T cells
in BALB/c mice (30).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 2.
Staining of lymphocytes isolated from mouse spleen,
cervical lymph node, and brain at 7 days post-TMEV infection. Isolated
lymphocytes were stained with either
Db:VP2121-130 tetramer (A to C) or control
irrelevant Db:E7 tetramer (D to F). The percentage of
CD8+ T cells that stain positive or negative for
Db:VP2121-130 or Db:E7
tetramer is given.
|
|
We next addressed CTL activity in the lymphocytes isolated
from the spleen and brain. In agreement with the staining shown by the
Db:VP2121-130 tetramer, RMA-S cells loaded
with VP2121-130 were killed by freshly isolated
CNS-ILs but not by lymphocytes isolated from the spleen (Fig.
3). In BALB/c mice infected with the JHM
strain of mouse hepatitis virus (JHMV), JHMV-specific CTL activity was
also localized only to the brain and not the cervical lymph node or
spleen (48). It is possible that in the case of these virus
infections, the brain acquires the responsibilities of a lymph node and
is the site of CTL expansion.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
Db:VP2121-130
epitope-specific cytolytic activity of lymphocytes isolated from the
brain and spleen at 7 days post-TMEV infection. RMA-S cells were loaded
with VP2121-130 peptide or irrelevant dEV8 peptide
before being subjected to killing by brain and spleen lymphocyte
preparations.
|
|
The hierarchy of immunodominance among peptides in TMEV
infection may be influenced by several factors. For example,
peripheral immunization of C57BL/6 mice with TMEV can induce
Kb-restricted splenocyte killing (21). In
addition, subtle variations in TMEV itself may alter immunodominance.
The TMEV protein L*, which is expressed by an alternative viral
reading frame, can influence mouse susceptibility to TMEV
infection and subsequent demyelinating disease (8).
Recently, it has been shown that intracranial infection of C57BL/6 mice
with the L*-deficient TMEV strain DAL* induces CNS-ILs capable of
Kb-restricted antiviral killing (23). Whether
these Kb-restricted epitopes are presented at low frequency
during intracranial infection of C57BL/6 mice with Daniel strain TMEV
remains to be established. Nevertheless, these results
demonstrate that TMEV peptides other than
VP2121-130 are potential antigens for C57BL/6
CD8+ T cells. Therefore, the observed dominance of
VP2121-130 as a T-cell epitope in
H-2Db-expressing mice must be regulated in some fashion.
To address how epitope dominance might be controlled, the influence of
costimulation, inflammatory cytokines, perforin, or CD4 help on
Db:VP2121-130 epitope dominance was
investigated in TMEV-infected genetic knockout mice. Class II
(34)-, CD4 (31)-, CD8 (31)-, IFN-
(unpublished observation)-, perforin (32)-,
and CD28 (unpublished observation)-deficient mice of the C57BL/6
lineage are all susceptible to TMEV persistent infection and
demyelinating disease despite expression of
H-2Db. To address the effects of these
inflammatory mediators which govern resistance to the virus, we
assessed the frequency of VP2121-130-specific T cells
among CNS-ILs in the brains of infected mice. CNS-ILs were isolated 7 days post-TMEV infection from mice deficient for the indicated
molecules and stained with Db:VP2121-130
tetramer and anti-CD8 antibodies. With the exception of the
CD8-deficient strain (Fig. 4E), all of
the other tested mouse strains developed a major population of T cells
at the site of infection that recognize VP2121-130
presented by Db (Fig. 4A to I). Furthermore, the
frequencies of these T cells in the class II, CD28, TNF-
RI, IFN-
,
and perforin knockout mice were not significantly different from that
found in infected C57BL/6 animals. This indicates that the homing and
clonal expansion of the population of
VP2121-130-specific CD8+ lymphocytes is
not affected by the absence of IFN-
, TNF-
RI, class II
molecules, perforin, or CD28. No staining by the
Db:VP2121-130 tetramer was observed in
TMEV-infected CD8
/
mice (Fig. 4E), demonstrating that
CD8 molecules are required for the development of T cells capable of
recognizing VP2121-130 in the context of
Db. The expression of CD8 molecules could influence the
development of the epitope-dominant T-cell response at the level of
repertoire selection, during T-cell activation, or in the process of
recruitment of T cells to the brain.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 4.
Frequency of CD8+ CNS-ILs that stain for
both Db:VP2121-130 tetramer and CD8 in
normal C57BL/6 mice (A), MHC-II / mice (C),
IFN- / mice (D), CD8 / mice (E),
CD28 / mice (F), CD4 / mice (G),
TNF- RI / mice (H), and perforin / mice
(I). Typical background staining of CNS-ILs from TMEV-infected C57BL/6
mice with an irrelevant Db:E7 tetramer is shown in panel B. Lymphocytes were isolated 7 days post-TMEV infection. The percentage of
CD8+ cells that stained with
Db:VP2121-130 tetramer is given in the
righthand corner. The CD8+ population that recognizes the
Db:VP2121-130 epitope is circles in panels
A and B but not in panels C to I.
|
|
The presence of significant populations of
Db:VP2121-130-specific CTL at the site
of TMEV infection in susceptible mice appears paradoxical at first
glance. However, it is clear that the activation of CTL is not the only
factor that can determine the outcome of viral infection. Lymphokines
released by T cells can have both direct antiviral function and
indirect influence on antiviral immunity by upregulating MHC encoded
antigen-presenting molecules and by recruiting other effector cells,
such as macrophages, to the site of infection. Cells harboring actively
replicating TMEV could avoid the immune response in the absence of the
timely upregulation of MHC gene expression or as a consequence of an inadequate cytokine response.
Of particular interest is the observation that CD4
/
mice consistently generate a lower but still appreciable (22 to 37%)
frequency of Db:VP2121-130-specific
CD8+ T cells in the brain. This indicates that the focus of
the CD8+ T-cell response on the VP2 peptide is indeed
regulated but the mechanism by which CD4 influences this process is not
clear. If T helper cells were important in maintaining the dominant
response to the VP2 epitope, then class II knockout mice would be
predicted to also display diminished epitope dominance in their
responses. As shown in Fig. 4C, this is not the case. The reason
for this discrepancy is not known, but it may be an indication that the functions of CD4 molecules are not completely understood. Perhaps CD4
molecules perform additional functions not involving interactions with
classically defined class II molecules. For example, another stage in
the development of the immune response where CD4 expression could
influence a CD8-restricted T-cell response is during the differentiation of immature T cells. Perhaps the absence of CD4 expression in the knockout mice at the CD4/CD8 double-positive stage in
the thymus diminishes their subsequent dominance in the hierarchy of
potential responding T cells to TMEV challenge. In addition, the
possibility that CD4 molecules could influence immune reactivity in
ways not yet appreciated must be considered.
Why the frequency of CD8+ T cells specific for a
single epitope is so high and how this frequency resists
change despite different environmental pressures remains unknown. The
inflammatory mediators studied affect the kinetics of an immune
response in several ways. For example, IFN-
can upregulate the
expression of many factors involved in antigen presentation, including
class I, class II,
2m, TAP1, TAP2, and tapasin
(4). Likewise, TNF-
can modify inflammation by either
working in synergy with IFN-
or by activating NF-
B through
degradation of the inhibitory subunit I
B (3, 47). Class
II-restricted help could also modify an inflammatory response by
providing the release of cytokines. Costimulation by B7-1 and B7-2
through CD28 is important for providing a second signal in T-cell
activation, perhaps even dictating whether a Th1 or a Th2 response will
occur (19). Perforin plays a central role in the effector
process of T-cell-mediated cell killing. The fact that the frequency of
VP2121-130 peptide-specific T cells is
essentially not different in perforin-deficient and normal
C57BL/6 mice, indicates that the factors leading to epitope dominance precede the effector phase of the response. Remarkably, the mechanism responsible for focusing the immune response on the
VP2121-130 peptide is not influenced by costimulation, class II-mediated help, or the effects of IFN-
or TNF-
.
As part of this study, we introduced a Db transgene into
the FVB strain to determine whether a population of
VP2121-130-specific CTLs could be generated in a
TMEV-infected mouse with a completely different genetic background.
Highly susceptible FVB mice are H-2q and
are not expected to generate Db-restricted CTL responses.
As predicted, no
Db:VP2121-130-specific T cells
were detected in the CNS-ILs of FVB mice (Fig.
5). Introduction of a Db
transgene into the FVB strain enables these highly susceptible mice to
resist TMEV-induced demyelinating disease (2). A major population (55%) of CNS-ILs isolated from TMEV-infected
FVB-Db transgenic mice stained with anti-CD8 and
Db:VP2121-130 tetramer (Fig. 5).
This frequency is similar to that observed in C57BL/6 mice (50 to
63%). This finding stresses the importance of the Db gene
in the VP2121-130-dominated T-cell response and the minimal effects contributed by other genes differing between these distantly related mouse strains.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 5.
Epitope dominance conferred by a Db
transgene. The staining patterns of CNS-ILs isolated from resistant FVB
(H-2Db) transgenic mice (A) and susceptible,
parental FVB (H-2q) mice (B) are shown.
CNS-ILs were stained with
Db:VP2121-130 tetramer and anti-CD8
antibodies and analyzed by FACS. The percentage of CD8+ T
cells that are double positive is given in the upper right corner of
panel A.
|
|
The concept of an immunodominant peptide eliciting a strong CTL
response is not new and has been described among both human and mouse
viral infections (9, 17, 28, 51). The mechanism by which
this occurs is not well understood, but peptide affinity, peptide
processing, and the available T-cell repertoire have all been
implicated as factors in establishing immunodominance hierarchies among
peptides (7, 9, 10, 16, 20, 29, 33, 46, 50, 52, 53). Here we
have demonstrated that the
Db:VP2121-130 epitope-restricted
clonal dominance appears to persist in the absence of key
inflammatory factors such as class II, CD4, CD28, IFN-
, and
TNF-
RI, indicating that the clonal dominance is independent of
interaction with CD8+ T cells and the help compartment.
 |
ACKNOWLEDGMENTS |
We thank the Mayo protein and flow cytometry core facilities for
assistance in tetramer staining and Becky Sanford for assistance in
bringing the manuscript to completion.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Mayo Clinic, 200 First St. SW, Rochester, MN 55905. Phone: (507) 284-8177. Fax: (507) 266-0981. E-mail: pease.larry{at}mayo.edu.
 |
REFERENCES |
| 1.
|
Altman, J. D.,
P. A. H. Moss,
P. J. R. Goulder,
D. H. Barouch,
M. G. McHeyzer-Williams,
J. I. Bell,
A. J. McMichael, and M. M. Davis.
1996.
Phenotypic analysis of antigen-specific T lymphocytes.
Science
274:94-96[Abstract/Free Full Text].
|
| 2.
|
Azoulay, A.,
M. Brahic, and J. F. Bureau.
1994.
FVB mice transgenic for the H-2D gene become resistant to persistent infection by Theiler's virus.
J. Virol.
68:4049-4052[Abstract/Free Full Text].
|
| 3.
|
Baldwin, A. S.
1996.
The NF-kB and IkB proteins: new discoveries and insights.
Annu. Rev. Immunol.
14:649-683[Medline].
|
| 4.
|
Boehm, U.,
T. Klamp,
M. Groot, and J. C. Howard.
1997.
Cellular responses to interferon- .
Annu. Rev. Immunol.
15:749-795[Medline].
|
| 5.
|
Borson, N. D.,
C. Paul,
X. Lin,
W. K. Nevala,
M. A. Strausbauch,
M. Rodriguez, and P. J. Wettstein.
1997.
Brain-infiltrating cytolytic T lymphocytes specific for Theiler's virus recognize H-2Db molecules complexed with a viral VP2 peptide lacking a consensus anchor residue.
J. Virol.
71:5244-5250[Abstract].
|
| 6.
|
Bradl, M., and C. Linington.
1996.
Animal models of demyelination.
Brain Pathol.
6:303-311[Medline].
|
| 7.
|
Cao, W.,
B. A. Meyers-Powell, and T. J. Braciale.
1996.
The weak CD8+ CTL response to an influenza hemagglutinin epitope reflects limited T cell availability.
J. Immunol.
157:505-511[Abstract].
|
| 8.
|
Chen, H.,
W. Kong,
L. Ziang,
P. L. Ward, and R. P. Roos.
1995.
A picornavirus protein synthesized out of frame with the polyprotein plays a key role in a virus-induced immune-mediated demyelinating disease.
Nat. Med.
1:927-931[Medline].
|
| 9.
|
Cole, G. A.,
T. L. Hogg, and D. L. Woodland.
1994.
The MHC class I-restricted T cell response to Sendai virus infection in C57BL/6 mice: a single immunodominant epitope elicits an extremely diverse repertoire of T cells.
Int. Immunol.
6:1767-1775[Abstract/Free Full Text].
|
| 10.
|
Deng, Y.,
J. W. Yewdell,
L. C. Eisenlohr, and J. R. Bennink.
1997.
MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL.
J. Immunol.
158:1507-1515[Abstract].
|
| 11.
|
Dethlefs, S.,
N. Escriou,
M. Brahic,
S. van der Werf, and E. L. Larsson-Sciard.
1997.
Theiler's virus and Mengo virus induce cross-reactive cytotoxic T lymphocytes restricted to the same immunodominant VP2 epitope in C57BL/6 mice.
J. Virol.
71:5361-5365[Abstract].
|
| 12.
|
Drescher, K. M.,
L. R. Pease, and M. Rodriguez.
1997.
Antiviral immune responses modulate the nature of central nervous system (CNS) disease in a murine model of multiple sclerosis.
Immunol. Rev.
159:177-193[Medline].
|
| 13.
|
Fiett, L.,
C. Aubert,
M. Brahic, and C. P. Rossi.
1993.
Theiler's virus infection of 2-microglobulin-deficient mice.
J. Virol.
67:589-592[Abstract/Free Full Text].
|
| 14.
|
Fiette, L.,
M. Brahic, and C. Pena-Rossi.
1996.
Infection of class-II deficient mice by the DA strain of Theiler's virus.
J. Virol.
70:4811-4815[Abstract].
|
| 15.
|
Garboczi, D. N.,
D. T. Hung, and D. C. Wiley.
1992.
HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides.
Proc. Natl. Acad. Sci. USA
89:3429-3433[Abstract/Free Full Text].
|
| 16.
|
Gournier, H.,
S. Pocolo,
C. A. Siegrist,
J. Jehan,
B. Peranau,
Z. Garcia,
T. Rose,
J. Neefjes, and F. A. Lemonnier.
1995.
Restriction of self-antigen presentation to cytolytic T lymphocytes by mouse peptide pumps.
Eur. J. Immunol.
25:2019-2026[Medline].
|
| 17.
|
Horwitz, M. S.,
Y. Yanagi, and M. B. A. Oldstone.
1993.
T-cell receptors from virus-specific cytotoxic T lymphocytes recognizing a single immunodominant nine-amino-acid viral epitope show marked diversity.
J. Virol.
68:352-357[Abstract/Free Full Text].
|
| 18.
|
Larsson-Sciard, E. L.,
S. Dethlefs, and M. Brahic.
1997.
In vivo administration of interleukin-2 protects susceptible mice from Theiler's virus persistence.
J. Virol.
71:797-799[Abstract].
|
| 19.
|
Lenschow, D. J.,
T. L. Walunas, and J. A. Bluestone.
1996.
CD28/B7 system of T cell costimulation.
Annu. Rev. Immunol.
14:233-258[Medline].
|
| 20.
|
Levitsky, V.,
Q.-J. Zhang,
J. Levitskaya, and M. G. Masucci.
1996.
The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
J. Exp. Med.
183:915-926[Abstract/Free Full Text].
|
| 21.
|
Lin, X.,
L. R. Pease, and M. Rodriguez.
1997.
Differential generation of class I H-2D-versus H-2K-restricted cytotoxicity against a demyelinating virus following central nervous system infection.
Eur. J. Immunol.
27:963-970[Medline].
|
| 22.
|
Lin, X.,
L. R. Pease,
P. D. Murray, and M. Rodriguez.
1998.
Theiler's virus infection of genetically susceptible mice induces central nervous system-infiltrating CTLs with no apparent viral or major myelin antigenic specificity.
J. Immunol.
160:5661-5668[Abstract/Free Full Text].
|
| 23.
|
Lin, X.,
R. P. Roos,
L. R. Pease,
P. Wettstein, and M. Rodriguez.
1999.
A Theiler's virus alternatively-initiated protein inhibits the generation of H-2K-restricted virus-specific cytotoxicity.
J. Immunol.
162:17-24[Abstract/Free Full Text].
|
| 24.
|
Lindsley, M. D., and M. Rodriguez.
1989.
Characterization of the inflammatory response in the central nervous system of mice susceptible to demyelination by Theiler's virus.
J. Immunol.
142:2677-2682[Abstract].
|
| 25.
|
Melero, I.,
M. C. Singhal,
P. McGowan,
H. S. Haugen,
J. Blake,
K. E. Hellstrom,
G. Yang,
C. H. Clegg, and L. Chen.
1997.
Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16.
J. Virol.
71:3998-4004[Abstract].
|
| 26.
|
Miller, S. D., and W. J. Karpus.
1994.
The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases.
Immunol. Today
16:356-361.
|
| 27.
|
Monteyne, P.,
J. F. Bureau, and M. Brahic.
1997.
The infection of mouse by Theiler's virus: from genetics to immunology.
Immunol. Rev.
159:163-176[Medline].
|
| 28.
|
Moss, P. A. H.,
R. J. Moots,
W. M. C. Rosenberg,
S. J. Rowland-Jones,
H. C. Bodmer,
A. J. McMichael, and J. I. Bell.
1991.
Extensive conservation of and chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide.
Proc. Natl. Acad. Sci. USA
88:8987-8990[Abstract/Free Full Text].
|
| 29.
|
Moudgil, K. M.,
D. S. Sekiguchi,
S. Y. Kim, and E. E. Sercarz.
1997.
Immunodominance is independent of structural constraints: each region within hen eggwhite lysozyme is potentially available upon processing of native antigen.
J. Immunol.
159:2574-2579[Abstract].
|
| 30.
|
Murali-Krishna, K.,
J. D. Altman,
M. Suresh,
D. J. D. Sourdive,
A. J. Zajac,
J. D. Miller,
J. Slasky, and R. Ahmed.
1998.
Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.
Immunity
8:177-187[Medline].
|
| 31.
|
Murray, P. D.,
K. D. Pavelko,
J. Leibowitz,
X. Lin, and M. Rodriguez.
1998.
CD4+ and CD8+ T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis.
J. Virol.
72:7320-7329[Abstract/Free Full Text].
|
| 32.
|
Murray, P. D.,
D. B. McGavern,
X. Lin,
M. K. Njenga,
J. Leibowitz,
L. R. Pease, and M. Rodriguez.
1998.
Perforin-dependent neurologic injury in a viral model of multiple sclerosis.
J. Neurosci.
18:7306-7314[Abstract/Free Full Text].
|
| 33.
|
Niedermann, G.,
S. Butz,
H. G. Ihlenfeldt,
R. Grimm,
M. Lucchiari,
H. Hoschutzky,
G. Jung,
B. Maier, and K. Eichmann.
1995.
Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules.
Immunity
2:289-299[Medline].
|
| 34.
|
Njenga, M. K.,
K. D. Pavelko,
J. Baisch,
W. Lin,
C. David,
J. Leibowitz, and M. Rodriguez.
1996.
Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice.
J. Virol.
70:1729-1737[Abstract].
|
| 35.
|
Njenga, M. K.,
K. Asakura,
S. F. Hunter,
P. Wettstein,
L. R. Pease, and M. Rodriguez.
1997.
The immune system preferentially clears Theiler's virus from the gray matter of the central nervous system.
J. Virol.
71:8592-8601[Abstract].
|
| 36.
|
Paya, C. V.,
A. Patick,
P. J. Leibson, and M. Rodriguez.
1989.
Role of natural killer cells as immune effectors in encephalitis and demyelination induced by Theiler's virus.
J. Immunol.
143:95-102[Abstract].
|
| 37.
|
Pullen, L. C.,
S. D. Miller,
M. Dal Canto, and B. S. Kim.
1993.
Class I-deficient resistant mice intracerebrally inoculated with Theiler's virus show an increased T cell response to viral antigens and susceptibility to demyelination.
Eur. J. Immunol.
23:2287-2293[Medline].
|
| 38.
|
Rodriguez, M., and C. S. David.
1995.
H-2 Dd transgene suppresses Theiler's virus-induced demyelination in susceptible strains of mice.
J. Neurovirol.
1:111-117[Medline].
|
| 39.
|
Rodriguez, M., and S. Subramaniam.
1988.
Successful therapy of Theiler's virus-induced demyelination (DA strain) with monoclonal anti-Lyt-2 antibody.
J. Immunol.
140:2950-2955[Abstract].
|
| 40.
|
Rodriguez, M.,
A. J. Dunkel,
R. L. Thiemann,
J. Leibowitz,
M. Zijlstra, and R. Jaenisch.
1993.
Abrogation of resistance to Theiler's virus-induced demyelination in H-2b mice deficient in 2-microglobulin.
J. Immunol.
151:266-276[Abstract].
|
| 41.
|
Rodriguez, M., and C. David.
1985.
Demyelination induced by Theiler's virus: influence of the H-2 haplotype.
J. Immunol.
135:2145-2148[Abstract].
|
| 42.
|
Rodriguez, M.,
J. Leibowitz, and C. S. David.
1986.
Susceptibility to Theiler's virus-induced demyelination: mapping of the gene within the H-2D region.
J. Exp. Med.
163:620-631[Abstract/Free Full Text].
|
| 43.
|
Rodriguez, M.,
K. D. Pavelko,
M. K. Njenga,
W. C. Logan, and P. J. Wettstein.
1996.
The balance between persistent virus infection and immune cells determines demyelination.
J. Immunol.
157:5699-5709[Abstract].
|
| 44.
|
Rodriguez, M.,
L. R. Pease, and C. S. David.
1986.
Immune-mediated injury of virus-infected oligodendrocytes.
Immunol. Today
7:359-363.
|
| 45.
|
Rossi, C. P.,
A. McAllister,
M. Tanguy,
D. Kagi, and M. Brahic.
1998.
Theiler's virus infection of perforin-deficient mice.
J. Virol.
72:4515-4519[Abstract/Free Full Text].
|
| 46.
|
Sette, A.,
A. Vitiello,
B. Reherman,
P. Fowler,
R. Nayersina,
W. M. Kast,
C. J. Melief,
C. Oseroff,
L. Yuan,
J. Ruppert,
J. Sidney,
M. del Guercio,
S. Southwood,
R. T. Kubo,
R. W. Chestnut,
H. M. Grey, and F. V. Chisari.
1994.
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
J. Immunol.
153:5586-5592[Abstract].
|
| 47.
|
Siebenlist, U.,
G. Franzoso, and K. Brown.
1994.
Structure, regulation, and function of NF-kB.
Annu. Rev. Cell Biol.
10:405-455.
|
| 48.
|
Stohlman, S. A.,
S. Kyuwa,
J. M. Polo,
D. Brady,
M. M. D. Lai, and C. C. Bergmann.
1993.
Characterization of mouse hepatitis virus-specific cytotoxic T cells derived from the central nervous system of mice infected with the JHM strain.
J. Virol.
67:7050-7059[Abstract/Free Full Text].
|
| 49.
|
Tallquist, M. D.,
T. J. Yun, and L. R. Pease.
1996.
A single T cell receptor recognizes structurally distinct MHC/peptide complexes with high specificity. J.
Exp. Med.
|
| 50.
|
Van den Burg, S. H.,
M. J. W. Visseren,
R. M. P. Brandt,
W. M. Kast, and C. J. M. Melief.
1996.
Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability.
J. Immunol.
156:3308-3314[Abstract].
|
| 51.
|
Van der Most, R. G.,
A. Sette,
C. Oseroff,
J. Alexander,
K. Murali-Krishna,
L. L. Lau,
S. Southwood,
J. Sidney,
R. W. Chesnut,
M. Matloubian, and R. Ahmed.
1996.
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection.
J. Immunol.
157:5543-5554[Abstract].
|
| 52.
|
Viner, N. J.,
C. A. Nelson, and E. R. Unanue.
1995.
Identification of a major I-Ek-restricted determinant of hen egg lysozyme: limitation of lymph node proliferation studies in defining immunodominance and crypticity.
Proc. Natl. Acad. Sci. USA
92:2214-2218[Abstract/Free Full Text].
|
| 53.
|
Yellen-Shaw, A. J.,
E. J. Wherry,
G. C. Dubois, and L. C. Eisenlohr.
1997.
Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein.
J. Immunol.
158:3227-3234[Abstract].
|
Journal of Virology, May 1999, p. 3702-3708, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rodriguez, M., Zoecklein, L., Kerkvliet, J. G., Pavelko, K. D., Papke, L., Howe, C. L., Pease, L. R., David, C.
(2008). Human HLA-DR Transgenes Protect Mice from Fatal Virus-Induced Encephalomyelitis and Chronic Demyelination. J. Virol.
82: 3369-3380
[Abstract]
[Full Text]
-
Johnson, A. J., Mendez-Fernandez, Y., Moyer, A. M., Sloma, C. R., Pirko, I., Block, M. S., Rodriguez, M., Pease, L. R.
(2005). Antigen-Specific CD8+ T Cells Mediate a Peptide-Induced Fatal Syndrome. J. Immunol.
174: 6854-6862
[Abstract]
[Full Text]
-
Mendez-Fernandez, Y. V., Hansen, M. J., Rodriguez, M., Pease, L. R.
(2005). Anatomical and Cellular Requirements for the Activation and Migration of Virus-Specific CD8+ T Cells to the Brain during Theiler's Virus Infection. J. Virol.
79: 3063-3070
[Abstract]
[Full Text]
-
Block, M. S., Mendez-Fernandez, Y. V., Van Keulen, V. P., Hansen, M. J., Allen, K. S., Taboas, A. L., Rodriguez, M., Pease, L. R.
(2005). Inability of bm14 Mice to Respond to Theiler's Murine Encephalomyelitis Virus Is Caused by Defective Antigen Presentation, Not Repertoire Selection. J. Immunol.
174: 2756-2762
[Abstract]
[Full Text]
-
Oleszak, E. L., Chang, J. R., Friedman, H., Katsetos, C. D., Platsoucas, C. D.
(2004). Theiler's Virus Infection: a Model for Multiple Sclerosis. Clin. Microbiol. Rev.
17: 174-207
[Abstract]
[Full Text]
-
Rodriguez, M., Zoecklein, L. J., Howe, C. L., Pavelko, K. D., Gamez, J. D., Nakane, S., Papke, L. M.
(2003). Gamma Interferon Is Critical for Neuronal Viral Clearance and Protection in a Susceptible Mouse Strain following Early Intracranial Theiler's Murine Encephalomyelitis Virus Infection. J. Virol.
77: 12252-12265
[Abstract]
[Full Text]
-
Wuthrich, M., Filutowicz, H. I., Warner, T., Deepe, G. S. Jr., Klein, B. S.
(2003). Vaccine Immunity to Pathogenic Fungi Overcomes the Requirement for CD4 Help in Exogenous Antigen Presentation to CD8+ T Cells: Implications for Vaccine Development in Immune-deficient Hosts. JEM
197: 1405-1416
[Abstract]
[Full Text]
-
Kang, B.-S., Lyman, M. A., Kim, B. S.
(2002). Differences in Avidity and Epitope Recognition of CD8+ T Cells Infiltrating the Central Nervous Systems of SJL/J Mice Infected with BeAn and DA Strains of Theiler's Murine Encephalomyelitis Virus. J. Virol.
76: 11780-11784
[Abstract]
[Full Text]
-
Wilcox, R. A., Flies, D. B., Wang, H., Tamada, K., Johnson, A. J., Pease, L. R., Rodriguez, M., Guo, Y., Chen, L.
(2002). Impaired Infiltration of Tumor-specific Cytolytic T Cells in the Absence of Interferon-{gamma} despite Their Normal Maturation in Lymphoid Organs during CD137 Monoclonal Antibody Therapy. Cancer Res.
62: 4413-4418
[Abstract]
[Full Text]
-
Lin, X., Njenga, M. K., Johnson, A. J., Pavelko, K. D., David, C. S., Pease, L. R., Rodriguez, M.
(2002). Transgenic Expression of Theiler's Murine Encephalomyelitis Virus Genes in H-2b Mice Inhibits Resistance to Virus-Induced Demyelination. J. Virol.
76: 7799-7811
[Abstract]
[Full Text]
-
Kang, B.-S., Lyman, M. A., Kim, B. S.
(2002). The Majority of Infiltrating CD8+ T Cells in the Central Nervous System of Susceptible SJL/J Mice Infected with Theiler's Virus Are Virus Specific and Fully Functional. J. Virol.
76: 6577-6585
[Abstract]
[Full Text]
-
Lyman, M. A., Lee, H.-G., Kang, B. S., Kang, H.-K., Kim, B. S.
(2002). Capsid-Specific Cytotoxic T Lymphocytes Recognize Three Distinct H-2Db-Restricted Regions of the BeAn Strain of Theiler's Virus and Exhibit Different Cytokine Profiles. J. Virol.
76: 3125-3134
[Abstract]
[Full Text]
-
Schell, T. D., Tevethia, S. S.
(2001). Control of Advanced Choroid Plexus Tumors in SV40 T Antigen Transgenic Mice Following Priming of Donor CD8+ T Lymphocytes by the Endogenous Tumor Antigen. J. Immunol.
167: 6947-6956
[Abstract]
[Full Text]
-
Topham, D. J., Cardin, R. C., Christensen, J. P., Brooks, J. W., Belz, G. T., Doherty, P. C.
(2001). Perforin and Fas in murine gammaherpesvirus-specific CD8+ T cell control and morbidity. J. Gen. Virol.
82: 1971-1981
[Abstract]
[Full Text]
-
Wang, B., Norbury, C. C., Greenwood, R., Bennink, J. R., Yewdell, J. W., Frelinger, J. A.
(2001). Multiple Paths for Activation of Naive CD8+ T Cells: CD4-Independent Help. J. Immunol.
167: 1283-1289
[Abstract]
[Full Text]
-
Block, M. S., Johnson, A. J., Mendez-Fernandez, Y., Pease, L. R.
(2001). Monomeric Class I Molecules Mediate TCR/CD3{{epsilon}}/CD8 Interaction on the Surface of T Cells. J. Immunol.
167: 821-826
[Abstract]
[Full Text]
-
Riberdy, J. M., Christensen, J. P., Branum, K., Doherty, P. C.
(2000). Diminished Primary and Secondary Influenza Virus-Specific CD8+ T-Cell Responses in CD4-Depleted Ig-/- Mice. J. Virol.
74: 9762-9765
[Abstract]
[Full Text]